On April 7, 2026, Nuvalent, Inc. submitted its New Drug Application to the FDA for neladalkib, targeting advanced ALK-positive non-small cell lung cancer in patients pre-treated with tyrosine kinase inhibitors. This filing reflects a significant step in the company's product development.